EDP Sciences logo
Submit your paper
Search
Menu
All issues Volume 33 (2026) Parasite, 33 (2026) 4 References
Open Access
Review
Issue
Parasite
Volume 33, 2026
Article Number 4
Number of page(s) 13
DOI https://doi.org/10.1051/parasite/2026006
Published online 05 February 2026
  1. Alipanahi P, Khosrojerdi A, Pagheh AS, Hatam-Nahavandi K, Ahmadpour E. 2025. From pathogen to cure: exploring the antitumor potential of Toxoplasma gondii. Infectious Agents and Cancer, 20, 39. [Google Scholar]
  2. Aljieli M, Rivière C, Lantier L, Moiré N, Lakhrif Z, Boussemart AF, Cnudde T, Lajoie L, Aubrey N, Ahmed EM, Dimier-Poisson I, Di-Tommaso A, Mévélec MN. 2024. Specific cell targeting by Toxoplasma gondii displaying functional single-chain variable fragment as a novel strategy; a proof of principle. Cells, 13, 975. [Google Scholar]
  3. Bahwal SA, Chen JJ, Lilin E, Hao T, Chen J, Carruthers VB, Lai J, Zhou X. 2022. Attenuated Toxoplasma gondii enhances the antitumor efficacy of anti-PD1 antibody by altering the tumor microenvironment in a pancreatic cancer mouse model. Journal of Cancer Research and Clinical Oncology, 148, 2743–2757. [Google Scholar]
  4. Baird JR, Byrne KT, Lizotte PH, Toraya-Brown S, Scarlett UK, Alexander MP, Sheen MR, Fox BA, Bzik DJ, Bosenberg M, Mullins DW, Turk MJ, Fiering S. 2013. Immune-mediated regression of established B16F10 melanoma by intratumoral injection of attenuated Toxoplasma gondii protects against rechallenge. Journal of Immunology, 190, 469–478. [Google Scholar]
  5. Baird JR, Fox BA, Sanders KL, Lizotte PH, Cubillos-Ruiz JR, Scarlett UK, Rutkowski MR, Conejo-Garcia JR, Fiering S, Bzik DJ. 2013. Avirulent Toxoplasma gondii generates therapeutic antitumor immunity by reversing immunosuppression in the ovarian cancer microenvironment. Cancer Research, 73, 3842–3851. [Google Scholar]
  6. Baker TL, Wright DK, Uboldi AD, Tonkin CJ, Vo A, Wilson T, McDonald SJ, Mychasiuk R, Semple BD, Sun M, Shultz SR. 2024. A pre-existing Toxoplasma gondii infection exacerbates the pathophysiological response and extent of brain damage after traumatic brain injury in mice. Journal of Neuroinflammation, 21, 14. [Google Scholar]
  7. Ballabh P, Braun A, Nedergaard M. 2004. The blood-brain barrier: an overview: structure, regulation, and clinical implications. Neurobiology of Disease, 16, 1–13. [Google Scholar]
  8. Banks WA. 2016. From blood-brain barrier to blood-brain interface: new opportunities for CNS drug delivery. Nature Reviews Drug Discovery, 15, 275–292. [Google Scholar]
  9. Beste C, Getzmann S, Gajewski PD, Golka K, Falkenstein M. 2014. Latent Toxoplasma gondii infection leads to deficits in goal-directed behavior in healthy elderly. Neurobiology of Aging, 35, 1037–1044. [Google Scholar]
  10. Biswas SK, Mantovani A. 2010. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nature Immunology, 11, 889–896. [Google Scholar]
  11. Blader IJ, Saeij JP. 2009. Communication between Toxoplasma gondii and its host: impact on parasite growth, development, immune evasion, and virulence. Acta Pathologica, Microbiologica, et Immunologica Scandinavica, 117, 458–476. [Google Scholar]
  12. Boghozian R, Saei A, Mirzaei R, Jamali A, Vaziri B, Razavi A, Hadjati J. 2015. Identification of Toxoplasma gondii protein fractions induce immune response against melanoma in mice, Infectious Agents and Cancer, 123, 800–809. [Google Scholar]
  13. Bracha S, Johnson HJ, Pranckevicius NA, Catto F, Economides AE, Litvinov S, Hassi K, Rigoli MT, Cheroni C, Bonfanti M, Valenti A, Stucchi S, Attreya S, Ross PD, Walsh D, Malachi N, Livne H, Eshel R, Krupalnik V, Levin D, Cobb S, Koumoutsakos P, Caporale N, Testa G, Aguzzi A, Koshy AA, Sheiner L, Rechavi O. 2024. Engineering Toxoplasma gondii secretion systems for intracellular delivery of multiple large therapeutic proteins to neurons. Nature Microbiology, 9, 2051–2072. [Google Scholar]
  14. Burke JM, Roberts CW, Hunter CA, Murray M, Alexander J. 1994. Temporal differences in the expression of mRNA for IL-10 and IFN-gamma in the brains and spleens of C57BL/10 mice infected with Toxoplasma gondii. Parasite Immunology, 16, 305–314. [Google Scholar]
  15. Caner A. 2021. Toxoplasma gondii could have a possible role in the cancer mechanism by modulating the host’s cell response. Acta Tropica, 220, 105966. [Google Scholar]
  16. Chandra A, MacEwan JP, Campinha-Bacote A, Khan ZM. 2016. Returns to society from investment in cancer research and development. Forum for Health Economics & Policy, 19, 71–86. [Google Scholar]
  17. Chang GN, Gabrielson DA. 1984. Toxoplasma gondii: growth in ovine fetal kidney cell cultures. Experimental Parasitology, 57, 81–85. [Google Scholar]
  18. Chen J, Liao W, Peng H. 2022. Toxoplasma gondii infection possibly reverses host immunosuppression to restrain tumor growth. Frontiers in Cellular and Infection Microbiology, 12, 959300. [Google Scholar]
  19. Chen M, Yang P, Xin Z, Chen J, Zou W, Zhou L, Yang L, Peng J, Peng H. 2023. Toxoplasma gondii gra5 deletion mutant protects hosts against Toxoplasma gondii infection and breast tumors. Frontiers in Immunology, 14, 1173379. [Google Scholar]
  20. Chen Q, Chen M, Liu Z. 2019. Local biomaterials-assisted cancer immunotherapy to trigger systemic antitumor responses. Chemical Society Reviews, 48, 5506–5526. [Google Scholar]
  21. Chowdhury S, Castro S, Coker C, Hinchliffe TE, Arpaia N, Danino T. 2019. Programmable bacteria induce durable tumor regression and systemic antitumor immunity. Nature Medicine, 25, 1057–1063. [Google Scholar]
  22. Chua YW, Chow SC. 2025. Bug as a drug: Unveiling anti-cancer properties of Toxoplasma gondii and its therapeutic prospects in cancer immunotherapy. Acta Tropica, 267, 107684. [Google Scholar]
  23. Combes F, Meyer E, Sanders NN. 2020. Immune cells as tumor drug delivery vehicles. Journal of Controlled Release, 327, 70–87. [Google Scholar]
  24. Coward J, Kulbe H, Chakravarty P, Leader D, Vassileva V, Leinster DA, Thompson R, Schioppa T, Nemeth J, Vermeulen J, Singh N, Avril N, Cummings J, Rexhepaj E, Jirström K, Gallagher WM, Brennan DJ, McNeish IA, Balkwill FR. 2011. Interleukin-6 as a therapeutic target in human ovarian cancer. Clinical Cancer Research, 17, 6083–6096. [Google Scholar]
  25. Cox TR. 2021. The matrix in cancer. Nature Reviews Cancer, 21, 217–238. [Google Scholar]
  26. Curiel TJ, Cheng P, Mottram P, Alvarez X, Moons L, Evdemon-Hogan M, Wei S, Zou L, Kryczek I, Hoyle G, Lackner A, Carmeliet P, Zou W. 2004. Dendritic cell subsets differentially regulate angiogenesis in human ovarian cancer. Cancer Research, 64, 5535–5538. [Google Scholar]
  27. Dasan B, Rajamanickam A, Munisankar S, Menon PA, Ahamed SF, Nott S, Babu S. 2023. Hookworm infection induces glycometabolic modulation in South Indian individuals with type 2 diabetes. IJID Regions, 9, 18–24. [Google Scholar]
  28. Dawant T, Wang W, Spriggs M, Magela de Faria Junior G, Horton L, Szafranski NM, Waap H, Jokelainen P, Gerhold RW, Su C. 2024. Isolation of Toxoplasma gondii in cell culture: an alternative to bioassay. International Journal for Parasitology, 54, 131–137. [Google Scholar]
  29. Ding H, Wu S, Jin Z, Zheng B, Hu Y, He K, Lu S, Zhuo X. 2022. Anti-tumor effect of parasitic protozoans. Bioengineering, 9, 395. [Google Scholar]
  30. Dolgin E. 2018. Bringing down the cost of cancer treatment. Nature, 555, S26–S29. [Google Scholar]
  31. du Plooy I, Mlangeni M, Christian R, Tsotetsi-Khambule AM. 2023. An African perspective on the genetic diversity of Toxoplasma gondii: A systematic review. Parasitology, 150, 551–578. [Google Scholar]
  32. Dupont CD, Christian DA, Selleck EM, Pepper M, Leney-Greene M, Harms Pritchard G, Koshy AA, Wagage S, Reuter MA, Sibley LD, Betts MR, Hunter CA. 2014. Parasite fate and involvement of infected cells in the induction of CD4+ and CD8+ T cell responses to Toxoplasma gondii. PLoS Pathogens, 10, e1004047. [Google Scholar]
  33. Dupont D, Robert MG, Brenier-Pinchart MP, Lefevre A, Wallon M, Pelloux H. 2023. Toxoplasma gondii, a plea for a thorough investigation of its oncogenic potential. Heliyon, 9, e22147. [Google Scholar]
  34. Dwivedi R, Pandey R, Chandra S, Mehrotra D. 2023. Dendritic cell-based immunotherapy: a potential player in oral cancer therapeutics. Immunotherapy, 15, 457–469. [Google Scholar]
  35. Fox BA, Falla A, Rommereim LM, Tomita T, Gigley JP, Mercier C, Cesbron-Delauw MF, Weiss LM, Bzik DJ. 2011. Type II Toxoplasma gondii KU80 knockout strains enable functional analysis of genes required for cyst development and latent infection. Eukaryotic Cell, 10, 1193–1206. [Google Scholar]
  36. Fox BA, Sanders KL, Rommereim LM, Guevara RB, Bzik DJ. 2016. Secretion of rhoptry and dense granule effector proteins by nonreplicating Toxoplasma gondii uracil auxotrophs controls the development of antitumor immunity. PLoS Genetics, 12, e1006189. [Google Scholar]
  37. Ganesh K, Wu C, O’Rourke KP, Szeglin BC, Zheng Y, Sauvé CG, Adileh M, Wasserman I, Marco MR, Kim AS, Shady M, Sanchez-Vega F, Karthaus WR, Won HH, Choi SH, Pelossof R, Barlas A, Ntiamoah P, Pappou E, Elghouayel A, Strong JS, Chen CT, Harris JW, Weiser MR, Nash GM, Guillem JG, Wei IH, Kolesnick RN, Veeraraghavan H, Ortiz EJ, Petkovska I, Cercek A, Manova-Todorova KO, Saltz LB, Lavery JA, DeMatteo RP, Massagué J, Paty PB, Yaeger R, Chen X, Patil S, Clevers H, Berger MF, Lowe SW, Shia J, Romesser PB, Dow LE, Garcia-Aguilar J, Sawyers CL, Smith JJ. 2019. A rectal cancer organoid platform to study individual responses to chemoradiation. Nature Medicine, 25, 1607–1614. [Google Scholar]
  38. Gazzinelli RT, Wysocka M, Hayashi S, Denkers EY, Hieny S, Caspar P, Trinchieri G, Sher A. 1994. Parasite-induced IL-12 stimulates early IFN-gamma synthesis and resistance during acute infection with Toxoplasma gondii. Journal of Immunology, 153, 2533–2543. [Google Scholar]
  39. Ghorbankhani GA, Mohammadi A, Kazemipur N, Morovati S, Gharesi Fard B, Nazifi Habibabadi S, Hashempour Sadeghian M. 2023. Apoptotic activity of Newcastle disease virus in comparison with nisin A in MDA-MB-231 cell line. Veterinary Research Forum, 14, 29–37. [Google Scholar]
  40. Hemminki O, Dos Santos JM, Hemminki A. 2020. Oncolytic viruses for cancer immunotherapy. Journal of Hematology & Oncology, 13, 84. [Google Scholar]
  41. Hibbs Jr JB, Lambert Jr LH, Remington JS. 1971. Resistance to murine tumors conferred by chronic infection with intracellular protozoa, Toxoplasma gondii and Besnoitia jellisoni. Journal of Infectious Diseases, 124, 587–592. [Google Scholar]
  42. Hodge JM, Coghill AE, Kim Y, Bender N, Smith-Warner SA, Gapstur S, Teras LR, Grimsrud TK, Waterboer T, Egan KM. 2021. Toxoplasma gondii infection and the risk of adult glioma in two prospective studies. International Journal of Cancer, 148, 2449–2456. [Google Scholar]
  43. Hu Z, Zhang Y, Xie Y, Yang J, Tang H, Fan B, Zeng K, Han Z, Lu J, Jiang H, Peng W, Li H, Chen H, Wu S, Shen B, Lun ZR, Yu X. 2024. The Toxoplasma effector GRA4 hijacks host TBK1 to oppositely regulate anti-T. gondii immunity and tumor immunotherapy. Advanced Science, 11, e2400952. [Google Scholar]
  44. Hunter CA, Yu D, Gee M, Ngo CV, Sevignani C, Goldschmidt M, Golovkina TV, Evans S, Lee WF, Thomas-Tikhonenko A. 2001 Cutting edge: systemic inhibition of angiogenesis underlies resistance to tumors during acute toxoplasmosis. Journal of Immunology, 166, 5878–5881. [Google Scholar]
  45. Hwang YS, Shin JH, Yang JP, Jung BK, Lee SH, Shin EH. 2018. Characteristics of infection immunity regulated by Toxoplasma gondii to maintain chronic infection in the brain. Frontiers in Immunology, 9, 158. [Google Scholar]
  46. Ibrahim HM, Bannai H, Xuan X, Nishikawa Y. 2009. Toxoplasma gondii cyclophilin 18-mediated production of nitric oxide induces bradyzoite conversion in a CCR5-dependent manner. Infection and Immunity, 77, 3686–3695. [Google Scholar]
  47. Iglesias-Escudero M, Arias-González N, Martínez-Cáceres E. 2023. Regulatory cells and the effect of cancer immunotherapy. Molecular Cancer, 22, 26. [Google Scholar]
  48. Ihara F, Fereig RM, Himori Y, Kameyama K, Umeda K, Tanaka S, Ikeda R, Yamamoto M, Nishikawa Y. 2020. Toxoplasma gondii dense granule proteins 7, 14, and 15 are involved in modification and control of the immune response mediated via NF-κB pathway. Frontiers in Immunology, 11, 1709. [Google Scholar]
  49. Ismail CA, Eissa MM, Gaafar MR, Younis LK, El Skhawy N. 2023. Toxoplasma gondii-derived antigen modifies tumor microenvironment of Ehrlich solid carcinoma murine model and enhances immunotherapeutic activity of cyclophosphamide. Medical Oncology, 40, 136. [Google Scholar]
  50. Kaur G, Roy B. 2024. Decoding Tumor Angiogenesis for therapeutic advancements: mechanistic insights. Biomedicines, 12, 827. [Google Scholar]
  51. Khan IA, Moretto M. 2022. Immune responses to Toxoplasma gondii. Current Opinion in Immunology, 77, 102226. [Google Scholar]
  52. Kim JO, Jung SS, Kim SY, Kim TY, Shin DW, Lee JH, Lee YH. 2007. Inhibition of Lewis lung carcinoma growth by Toxoplasma gondii through induction of Th1 immune responses and inhibition of angiogenesis. Journal of Korean Medical Science, 22 Suppl, S38–S46. [Google Scholar]
  53. Kumar P, Tomita T, Gerken TA, Ballard CJ, Lee YS, Weiss LM, Samara NL. 2024. A Toxoplasma gondii O-glycosyltransferase that modulates bradyzoite cyst wall rigidity is distinct from host homologues. Nature Communications, 15, 3792. [Google Scholar]
  54. Lachenmaier SM, Deli MA, Meissner M, Liesenfeld O. 2011. Intracellular transport of Toxoplasma gondii through the blood-brain barrier. Journal of Neuroimmunology, 232, 119–130. [Google Scholar]
  55. Lee SH, Hu W, Matulay JT, Silva MV, Owczarek TB, Kim K, Chua CW, Barlow LJ, Kandoth C, Williams AB, Bergren SK, Pietzak EJ, Anderson CB, Benson MC, Coleman JA, Taylor BS, Abate-Shen C, McKiernan JM, Al-Ahmadie H, Solit DB, Shen MM. 2018. Tumor evolution and drug response in patient-derived organoid models of bladder cancer. Cell, 173, 515–528.e517. [CrossRef] [PubMed] [Google Scholar]
  56. Li K, Shi H, Zhang B, Ou X, Ma Q, Chen Y, Shu P, Li D, Wang Y. 2021. Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer. Signal Transduction and Targeted Therapy, 6, 362. [Google Scholar]
  57. Liu YT, Sun ZJ. 2021. Turning cold tumors into hot tumors by improving T-cell infiltration. Theranostics, 11, 5365–5386. [CrossRef] [PubMed] [Google Scholar]
  58. Lotfalizadeh N, Sadr S, Morovati S, Lotfalizadeh M, Hajjafari A, Borji H. 2024. A potential cure for tumor-associated immunosuppression by Toxoplasma gondii. Cancer Reports, 7, e1963. [Google Scholar]
  59. Mahmoudvand H, Ziaali N, Ghazvini H, Shojaee S, Keshavarz H, Esmaeilpour K, Sheibani V. 2016. Toxoplasma gondii Infection promotes neuroinflammation through cytokine networks and induced hyperalgesia in BALB/c mice. Inflammation, 39, 405–412. [Google Scholar]
  60. Matos LC, Machado JP, Monteiro FJ, Greten HJ. 2021. Understanding traditional Chinese medicine therapeutics: an overview of the basics and clinical applications. Healthcare, 9, 257. [Google Scholar]
  61. Mercer HL, Snyder LM, Doherty CM, Fox BA, Bzik DJ, Denkers EY. 2020. Toxoplasma gondii dense granule protein GRA24 drives MyD88-independent p38 MAPK activation, IL-12 production and induction of protective immunity. PLoS Pathogens, 16, e1008572. [Google Scholar]
  62. Merritt EF, Kochanowsky JA, Hervé P, Watson AA, Koshy AA. 2024. Toxoplasma type II effector GRA15 has limited influence in vivo. PLoS One, 19, e0300764. [Google Scholar]
  63. Miyahara K, Yokoo N, Sakurai H, Igarashi I, Sakata Y, Yoshida Y, Saito A, Hirose T, Suzuki N. 1992. Antitumor activity of Toxoplasma lysate antigen against methylcholanthrene-induced tumor-bearing rats. Journal of Veterinary Medical Science, 54, 221–228. [Google Scholar]
  64. Nandini DB, Rao RS, Hosmani J, Khan S, Patil S, Awan KH. 2020. Novel therapies in the management of oral cancer: An update. Disease-a-Month, 66, 101036. [Google Scholar]
  65. Neal JT, Li X, Zhu J, Giangarra V, Grzeskowiak CL, Ju J, Liu IH, Chiou SH, Salahudeen AA, Smith AR, Deutsch BC, Liao L, Zemek AJ, Zhao F, Karlsson K, Schultz LM, Metzner TJ, Nadauld LD, Tseng YY, Alkhairy S, Oh C, Keskula P, Mendoza-Villanueva D, De La Vega FM, Kunz PL, Liao JC, Leppert JT, Sunwoo JB, Sabatti C, Boehm JS, Hahn WC, Zheng GXY, Davis MM, Kuo CJ. 2018. Organoid modeling of the tumor immune microenvironment. Cell, 175, 1972–1988.e1916. [CrossRef] [PubMed] [Google Scholar]
  66. Nimgaonkar VL, Yolken RH, Wang T, Chang CC, McClain L, McDade E, Snitz BE, Ganguli M. 2016. Temporal cognitive decline associated with exposure to infectious agents in a population-based, aging cohort. Alzheimer Disease and Associated Disorders, 30, 216–222. [Google Scholar]
  67. Oladejo M, Paterson Y, Wood LM. 2021. Clinical experience and recent advances in the development of Listeria-based tumor immunotherapies. Frontiers in Immunology, 12, 642316. [Google Scholar]
  68. Palucka K, Banchereau J. 2012. Cancer immunotherapy via dendritic cells. Nature Reviews Cancer, 12, 265–277. [Google Scholar]
  69. Pardridge WM. 2015. Targeted delivery of protein and gene medicines through the blood-brain barrier. Clinical Pharmacology and Therapeutics, 97, 347–361. [Google Scholar]
  70. Paredes-Santos T, Wang Y, Waldman B, Lourido S, Saeij JP. 2019. The GRA17 parasitophorous vacuole membrane permeability pore contributes to bradyzoite viability. Frontiers in Cellular and Infection Microbiology, 9, 321. [Google Scholar]
  71. Payne TM, Molestina RE, Sinai AP. 2003. Inhibition of caspase activation and a requirement for NF-kappaB function in the Toxoplasma gondii-mediated blockade of host apoptosis. Journal of Cell Science, 116, 4345–4358. [Google Scholar]
  72. Peng Z, Cheng S, Kou Y, Wang Z, Jin R, Hu H, Zhang X, Gong JF, Li J, Lu M, Wang X, Zhou J, Lu Z, Zhang Q, Tzeng DTW, Bi D, Tan Y, Shen L. 2020. The gut microbiome is associated with clinical response to anti-PD-1/PD-L1 immunotherapy in gastrointestinal cancer. Cancer Immunology Research, 8, 1251–1261. [Google Scholar]
  73. Perry CE, Gale SD, Erickson L, Wilson E, Nielsen B, Kauwe J, Hedges DW. 2016. Seroprevalence and serointensity of latent Toxoplasma gondii in a sample of elderly adults with and without Alzheimer disease. Alzheimer Disease and Associated Disorders, 30, 123–126. [Google Scholar]
  74. Polak R, Zhang ET, Kuo CJ. 2024. Cancer organoids 2.0: modelling the complexity of the tumour immune microenvironment. Nature Reviews Cancer, 24, 523–539. [Google Scholar]
  75. Pyo KH, Jung BK, Xin CF, Lee YW, Chai JY, Shin EH. 2014. Prominent IL-12 production and tumor reduction in athymic nude mice after Toxoplasma gondii lysate antigen treatment. Korean Journal of Parasitology, 52, 605–612. [Google Scholar]
  76. Pyo KH, Lee YW, Lim SM, Shin EH. 2016. Immune adjuvant effect of a Toxoplasma gondii profilin-like protein in autologous whole-tumor-cell vaccination in mice. Oncotarget, 7, 74107–74119. [Google Scholar]
  77. Raja J, Ludwig JM, Gettinger SN, Schalper KA, Kim HS. 2018. Oncolytic virus immunotherapy: future prospects for oncology. Journal for Immunotherapy of Cancer, 6, 140. [Google Scholar]
  78. Rosowski EE, Lu D, Julien L, Rodda L, Gaiser RA, Jensen KD, Saeij JP. 2011. Strain-specific activation of the NF-kappaB pathway by GRA15, a novel Toxoplasma gondii dense granule protein. Journal of Experimental Medicine, 208, 195–212. [Google Scholar]
  79. Ross EC, Olivera GC, Barragan A. 2022. Early passage of Toxoplasma gondii across the blood-brain barrier. Trends in Parasitology, 38, 450–461. [Google Scholar]
  80. Sadr S, Borji HJCCTR. 2023. Echinococcus granulosus as a promising therapeutic agent against triplenegative breast cancer. Current Cancer Therapy Reviews, 19, 292–297. [Google Scholar]
  81. Sadr S, Ghiassi S, Lotfalizadeh N, Simab PA, Hajjafari A, Borji H. 2023. Antitumor mechanisms of molecules secreted by Trypanosoma cruzi in colon and breast cancer: A review. Anti-Cancer Agents in Medicinal Chemistry, 23, 1710–1721. [Google Scholar]
  82. Sadr S, Yousefsani Z, Simab PA, Alizadeh AJR, Lotfalizadeh N, HJWsVJ Borji. 2023. Trichinella spiralis as a potential antitumor agent: An update. World’s Veterinary Journal, 13, 65–74. [Google Scholar]
  83. Saeij JP, Boyle JP, Boothroyd JC. 2005. Differences among the three major strains of Toxoplasma gondii and their specific interactions with the infected host. Trends in Parasitology, 21, 476–481. [Google Scholar]
  84. Sanchez SG, Besteiro S. 2021. The pathogenicity and virulence of Toxoplasma gondii. Virulence, 12, 3095–3114. [CrossRef] [PubMed] [Google Scholar]
  85. Sanders KL, Fox BA, Bzik DJ. 2015. Attenuated Toxoplasma gondii stimulates immunity to pancreatic cancer by manipulation of myeloid cell populations. Cancer Immunology Research, 3, 891–901. [Google Scholar]
  86. Sasai M, Yamamoto M. 2019. Innate, adaptive, and cell-autonomous immunity against Toxoplasma gondii infection. Experimental & Molecular Medicine, 51, 1–10. [Google Scholar]
  87. Seo SH, Kim SG, Shin JH, Ham DW, Shin EH. 2020. Toxoplasma GRA16 inhibits NF-κB activation through PP2A–B55 upregulation in non-small-cell lung carcinoma cells. International Journal of Molecular Sciences, 21, 6642. [Google Scholar]
  88. Snyder LM, Doherty CM, Mercer HL, Denkers EY. 2021. Induction of IL-12p40 and type 1 immunity by Toxoplasma gondii in the absence of the TLR-MyD88 signaling cascade. PLoS Pathogens, 17, e1009970. [Google Scholar]
  89. Song Y, Yuan H, Yang X, Yang Z, Ren Z, Qi S, He H, Zhang XX, Jiang T, Yuan ZG. 2024. The opposing effect of acute and chronic Toxoplasma gondii infection on tumor development. Parasites & Vectors, 17, 247. [Google Scholar]
  90. Su C, Khan A, Zhou P, Majumdar D, Ajzenberg D, Dardé ML, Zhu XQ, Ajioka JW, Rosenthal BM, Dubey JP, Sibley LD. 2012. Globally diverse Toxoplasma gondii isolates comprise six major clades originating from a small number of distinct ancestral lineages. Proceedings of the National Academy of Sciences of the United States of America, 109, 5844–5849. [Google Scholar]
  91. Subauste CS, Wessendarp M. 2000. Human dendritic cells discriminate between viable and killed Toxoplasma gondii tachyzoites: dendritic cell activation after infection with viable parasites results in CD28 and CD40 ligand signaling that controls IL-12-dependent and -independent T cell production of IFN-gamma. Journal of Immunology, 165, 1498–1505. [Google Scholar]
  92. Sukhumavasi W, Egan CE, Warren AL, Taylor GA, Fox BA, Bzik DJ, Denkers EY. 2008. TLR adaptor MyD88 is essential for pathogen control during oral toxoplasma gondii infection but not adaptive immunity induced by a vaccine strain of the parasite. Journal of Immunology, 181, 3464–3473. [Google Scholar]
  93. Swartz MA, Iida N, Roberts EW, Sangaletti S, Wong MH, Yull FE, Coussens LM, DeClerck YA. 2012. Tumor microenvironment complexity: emerging roles in cancer therapy. Cancer Research, 72, 2473–2480. [Google Scholar]
  94. Taniguchi K, Karin M. 2014. IL-6 and related cytokines as the critical lynchpins between inflammation and cancer. Seminars in Immunology, 26, 54–74. [Google Scholar]
  95. Tomita T, Bzik DJ, Ma YF, Fox BA, Markillie LM, Taylor RC, Kim K, Weiss LM. 2013. The Toxoplasma gondii cyst wall protein CST1 is critical for cyst wall integrity and promotes bradyzoite persistence. PLoS Pathogens, 9, e1003823. [Google Scholar]
  96. Torre LA, Siegel RL, Ward EM, Jemal A. 2016. Global cancer incidence and mortality rates and trends – an update. Cancer Epidemiology, Biomarkers & Prevention, 25, 16–27. [Google Scholar]
  97. Vittecoq M, Elguero E, Lafferty KD, Roche B, Brodeur J, Gauthier-Clerc M, Missé D, Thomas F. 2012. Brain cancer mortality rates increase with Toxoplasma gondii seroprevalence in France. Infection, Genetics and Evolution, 12, 496–498. [Google Scholar]
  98. Walther D, Smout M, Giacomin P, Brindley PJ, Mitreva M, Moyle M, Loukas A. 2025. Genetically modified helminths as pharmaceutical biofactories. Advances in Parasitology, 129, 75–114. [Google Scholar]
  99. Xiao J, Li Y, Prandovszky E, Kannan G, Viscidi RP, Pletnikov MV, Yolken RH. 2016. Behavioral abnormalities in a mouse model of chronic toxoplasmosis are associated with MAG1 antibody levels and cyst burden. PLoS Neglected Tropical Diseases, 10, e0004674. [Google Scholar]
  100. Xiao J, Savonenko A, Yolken RH. 2022. Strain-specific pre-existing immunity: A key to understanding the role of chronic Toxoplasma infection in cognition and Alzheimer’s diseases? Neuroscience and Biobehavioral Reviews, 137, 104660. [Google Scholar]
  101. Xie Y, Wang J, Wang Y, Wen Y, Pu Y, Wang B. 2024. Parasite-enhanced immunotherapy: transforming the “cold” tumors to “hot” battlefields. Cell Communication and Signaling, 22, 448. [Google Scholar]
  102. Xu LQ, Yao LJ, Jiang D, Zhou LJ, Chen M, Liao WZ, Zou WH, Peng HJ. 2021. A uracil auxotroph Toxoplasma gondii exerting immunomodulation to inhibit breast cancer growth and metastasis. Parasites & Vectors, 14, 601. [Google Scholar]
  103. Yang J, Yang C, Qian J, Li F, Zhao J, Fang R. 2020. Toxoplasma gondii α-amylase deletion mutant is a promising vaccine against acute and chronic toxoplasmosis. Microbial Biotechnology, 13, 2057–2069. [Google Scholar]
  104. Yarovinsky F, Zhang D, Andersen JF, Bannenberg GL, Serhan CN, Hayden MS, Hieny S, Sutterwala FS, Flavell RA, Ghosh S, Sher A. 2005. TLR11 activation of dendritic cells by a protozoan profilin-like protein. Science, 308, 1626–1629. [Google Scholar]
  105. Ye H, Zhou X, Zhu B, Xiong T, Huang W, He F, Li H, Chen L, Tang L, Ren Z. 2024. Toxoplasma gondii suppresses proliferation and migration of breast cancer cells by regulating their transcriptome. Cancer Cell International, 24, 144. [Google Scholar]
  106. Yeh YH, Hsiao HF, Yeh YC, Chen TW, Li TK. 2018. Inflammatory interferon activates HIF-1α-mediated epithelial-to-mesenchymal transition via PI3K/AKT/mTOR pathway. Journal of Experimental & Clinical Cancer Research, 37, 70. [Google Scholar]
  107. Yi-fan WU F-lL. 2017. Application of nonreplicating avirulent uracil auxotroph vaccine strain of Toxoplasma gondii in tumor immunotherapy. Chinese Journal of Parasitology and Parasitic Diseases, 35(3), 288–293. [Google Scholar]
  108. Zhang Y, Jin G, Zhang J, Mi R, Zhou Y, Fan W, Cheng S, Song W, Zhang B, Ma M, Liu F. 2018. Overexpression of STAT1 suppresses angiogenesis under hypoxia by regulating VEGF‑A in human glioma cells. Biomedicine & Pharmacotherapy, 104, 566–575. [Google Scholar]
  109. Zhang Y, Li D, Lu S, Zheng B. 2022. Toxoplasmosis vaccines: What we have and where to go? NPJ Vaccines, 7, 131. [Google Scholar]
  110. Zhao H, Wu L, Yan G, Chen Y, Zhou M, Wu Y, Li Y. 2021. Inflammation and tumor progression: signaling pathways and targeted intervention. Signal Transduction and Targeted Therapy, 6, 263. [Google Scholar]
  111. Zhao LX, Sun Q, Wang C, Liu JJ, Yan XR, Shao MC, Yu L, Xu WH, Xu R. 2024. Toxoplasma gondii-derived exosomes: A potential immunostimulant and delivery system for tumor immunotherapy superior to Toxoplasma gondii. International Journal of Nanomedicine, 19, 12421–12438. [Google Scholar]
  112. Zheng Z, Lu X, Zhou D, Deng XF, Liu QX, Liu XB, Zhang J, Li YQ, Zheng H, Dai JG. 2023. A novel enemy of cancer: recent investigations into protozoan anti-tumor properties. Frontiers in Cellular and Infection Microbiology, 13, 1325144. [Google Scholar]
  113. Zhou S, Gravekamp C, Bermudes D, Liu K. 2018. Tumour-targeting bacteria engineered to fight cancer. Nature Reviews Cancer, 18, 727–743. [Google Scholar]
  114. Zhu S, Lu J, Lin Z, Abuzeid AMI, Chen X, Zhuang T, Gong H, Mi R, Huang Y, Chen Z, Li G. 2022. Anti-tumoral effect and action mechanism of exosomes derived from Toxoplasma gondii-infected dendritic cells in mice colorectal cancer. Frontiers in Oncology, 12, 870528. [Google Scholar]
  115. Zhu YC, Elsheikha HM, Wang JH, Fang S, He JJ, Zhu XQ, Chen J. 2021. Synergy between Toxoplasma gondii type I ΔGRA17 immunotherapy and PD-L1 checkpoint inhibition triggers the regression of targeted and distal tumors. Journal for ImmunoTherapy of Cancer, 9, e002970. [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.